Hence, in glioblastoma patients with methylated MGMT promoter, combined (chemoradiation) treatment is more efficient, and a survival advantage can be observed compared to patients with unmethylated MGMT promoter (Chinot et al., 2007; Eoli et al., 2007; Hegi et al., 2005). Here, MGMT is linked to glioblastoma.